National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Dupilumab (Dupixent®)

Dupilumab (Dupixent®) is indicated for treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy.

NCPE Assessment Process Complete
Rapid review commissioned 13/11/2017
Rapid review completed 24/11/2017
Rapid Review outcome Full pharmacoeconomic assessment recommended
Full pharmacoeconomic assessment commissioned by the HSE 29/11/2017
Pre-submission consultation with Applicant 18/06/2018
Submission received from Applicant 25/03/2019
Preliminary review sent to Applicant 05/06/2019
NCPE assessment re-commenced 01/07/2019
Factual accuracy sent to Applicant 08/11/2019
NCPE assessment re-commenced 22/11/2019
NCPE assessment completed 12/12/2019
NCPE assessment outcome The NCPE recommends that dupilumab be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*

 Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.


The HSE has approved reimbursement following confidential price negotiations April 2021.